RxDoctor Payments Data

Barry Dublin, MD

Internal Medicine · Brooklyn, NYNPI 1649332818

Payments from drug & device makers

$1,741in general payments, 2019–2025

Across 75 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$683
  • Bayer$227
  • Otsuka America Pharmaceutical, Inc.$206
  • GSK$155
  • Smith+Nephew$83
  • Lilly USA, LLC$77
  • plus $310 from 7 others

What the payments were for

  • Food & beverage$1,70598%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,741 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$104,009
Medicare patients
123
Services billed
938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$137,153
JanuviaSitagliptin Phosphate67$71,441
TrulicityDulaglutide43$56,059
BiktarvyBictegrav/Emtricit/Tenofov Ala13$49,534
OzempicSemaglutide45$47,442
EntrestoSacubitril/Valsartan35$39,664
XareltoRivaroxaban32$39,524
JardianceEmpagliflozin39$35,523
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$27,602
FarxigaDapagliflozin Propanediol16$23,872
SantylCollagenase Clostridium Hist.39$20,613
Breo ElliptaFluticasone/Vilanterol33$16,404
LinzessLinaclotide26$13,710
TradjentaLinagliptin19$12,242
Incruse ElliptaUmeclidinium Bromide19$11,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$137,153117 claims
Lilly USA, LLCTrulicity$77$56,05943 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$155$55,84393 claims
GileadBiktarvy$21$49,53413 claims
AstraZenecaFarxiga, Symbicort$53$28,52229 claims
Smith+NephewSantyl$83$20,61339 claims
AbbVieLinzess$683$13,71026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →